Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03997786 · ClinicalTrials.gov registry record · Phase 2
A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis
A Phase 2 study of Moderate-to-severe Chronic Plaque Psoriasis, sponsored by Sun Pharmaceutical Industries Limited.
- Active
- Registry status
- Phase 2
- Development phase
- 135
- Enrollment target
- 20
- Study locations
NCT03997786 is a Phase 2 study of Moderate-to-severe Chronic Plaque Psoriasis that is active but no longer recruiting, run by Sun Pharmaceutical Industries Limited. The registered enrollment target is 135 participants, below the 183-participant average among 3 other Moderate-to-severe Chronic Plaque Psoriasis trials with a reported enrollment target (26% lower). The trial reports 20 study locations across 4 states.
The verdict
NCT03997786, a Phase 2 study of Moderate-to-severe Chronic Plaque Psoriasis, is active but no longer recruiting, sponsored by Sun Pharmaceutical Industries Limited.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 135 participants
- Enrollment target
- 20
- Study locations
Study Summary
The study has been designed with three components. Part A is an open label PK study followed by a randomized trial component (Part B) followed by open label Long Term Extension (LTE). The initial PK analysis is first done in adolescent subjects (12 to \<18 years) before initiating the PK study in younger cohort (6 to \<12 years)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tildrakizumab
Study Locations (20)
Other
- Site 63 - Budapest
- Site 62 - Budapest
- Site 61 - Debrecen
- Site 64 - Kaposvár
- Site 79 - Ahmedabad
- Site 71 - Lucknow
- Site 74 - Surat
- Site 57 - Bialystok
- Site 51 - Katowice
- Site 54 - Lodz
- Site 56 - Lodz
- Site 58 - Lublin
- Site 50 - Ostrowiec Świętokrzyski
- Site 59 - Sosnowiec
- Site 52 - Szczecin
California
- Site 1 - Fountain Valley
- Site 2 - Thousand Oaks
Florida
- Site 20 - Miami
- Site 7 - Miami
Washington
- Site 14 - Spokane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2020-01-15 |
| Est. Completion | 2031-08-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03997786
The ClinicalTrials.gov registry entry for NCT03997786 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 135 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 183-participant average among 3 other Moderate-to-severe Chronic Plaque Psoriasis trials with a reported enrollment target (26% lower). The listed sponsor is Sun Pharmaceutical Industries Limited, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Moderate-to-severe Chronic Plaque Psoriasis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT03997786 reports 20 study locations spanning 4 distinct geographic areas - top geographies include Other, California, Florida.
Frequently Asked Questions
What is clinical trial NCT03997786 about?
NCT03997786 is a clinical study titled "A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis". The study has been designed with three components. Part A is an open label PK study followed by a randomized trial component (Part B) followed by open label Long Term Extension (LTE). The initial PK analysis is first done in adolescent subjects (12 to \<18 years) before initiating the PK study in y...
What is the current status of trial NCT03997786?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 135 participants. The study started on 2020-01-15. Estimated completion is 2031-08-05.
What conditions does trial NCT03997786 study?
This clinical trial studies the following conditions: Moderate-to-severe Chronic Plaque Psoriasis.
What interventions are being tested in trial NCT03997786?
The interventions under investigation include: Placebo (DRUG), Tildrakizumab (DRUG).
Who is sponsoring clinical trial NCT03997786?
This trial is sponsored by Sun Pharmaceutical Industries Limited, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03997786 being conducted?
This trial has 20 study locations across California, Florida, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Moderate-to-severe Chronic Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Phase IIa Study of Multiple Doses of AbGn-168H by iv Infusion in Moderate to Severe Chronic Plaque Psoriasis Patients
COMPLETED · Phase 2
-
A Study to Evaluate the Safety and Effectiveness of Doxercalciferol Capsules in Participants With Moderate to Severe Psoriasis
COMPLETED · Phase 2
-
Comparing Efficacy and Safety of Bmab 1200 and Stelara in Patients With Moderate to Severe Chronic Plaque Psoriasis
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.